TY - JOUR
T1 - GABRG1 variant as a potential novel cause of epileptic encephalopathy, hypotonia, and global developmental delay
AU - Williams, Aaron
AU - Cooney, Erin
AU - Segal, Gabrielle
AU - Narayanan, Swetha
AU - Morand, Megan
AU - Agadi, Satish
N1 - Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/12
Y1 - 2022/12
N2 - Epileptic encephalopathies (EEs) are severe brain disorders with excessive ictal (seizure) and interictal (electrographic epileptiform discharges) activity in developing brain which may result in progressive cognitive and neuropsychological deterioration. In contrast to regular epilepsy where the treatment goal is to prevent the seizure (ictal) recurrence, in patients with EE the goal is to treat both ictal as well as interictal activity to prevent further progression. With the introduction of genetic sequencing technologies over the past 20 years, there is growing recognition of the genetic basis of EE, with the majority due to monogenic causes. Monogenic etiologies of EE include pathogenic variants in the γ-aminobutyric acid type A receptor (GABA-A) encoding gene family. We present a 2-year-old patient with EE, hypotonia, and global developmental delays. Clinical trio exome sequencing showed a novel, de novo variant in GABRG1. GABRG1 encodes the γ1 subunit of the GABA-A receptor. To date, there has not been an association of EE with pathogenic variants in GABRG1. This variant is predicted to be damaging to protein structure and function, and the patient's phenotype is similar to those with pathogenic variants in other members of the GABA-A receptor encoding gene family.
AB - Epileptic encephalopathies (EEs) are severe brain disorders with excessive ictal (seizure) and interictal (electrographic epileptiform discharges) activity in developing brain which may result in progressive cognitive and neuropsychological deterioration. In contrast to regular epilepsy where the treatment goal is to prevent the seizure (ictal) recurrence, in patients with EE the goal is to treat both ictal as well as interictal activity to prevent further progression. With the introduction of genetic sequencing technologies over the past 20 years, there is growing recognition of the genetic basis of EE, with the majority due to monogenic causes. Monogenic etiologies of EE include pathogenic variants in the γ-aminobutyric acid type A receptor (GABA-A) encoding gene family. We present a 2-year-old patient with EE, hypotonia, and global developmental delays. Clinical trio exome sequencing showed a novel, de novo variant in GABRG1. GABRG1 encodes the γ1 subunit of the GABA-A receptor. To date, there has not been an association of EE with pathogenic variants in GABRG1. This variant is predicted to be damaging to protein structure and function, and the patient's phenotype is similar to those with pathogenic variants in other members of the GABA-A receptor encoding gene family.
KW - GABA-A receptor
KW - GABRG1
KW - epileptic encephalopathies
UR - http://www.scopus.com/inward/record.url?scp=85138266586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138266586&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.62969
DO - 10.1002/ajmg.a.62969
M3 - Article
C2 - 36121006
AN - SCOPUS:85138266586
SN - 1552-4825
VL - 188
SP - 3546
EP - 3549
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 12
ER -